ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,171.56
0.31%
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs Yen
158.0815
0.08%
Brent Oil
84.605
-0.11%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Eledon Pharmaceuticals Inc (ELDN)

  7. Eledon Pharmaceuticals Inc (ELDN) ニュース

ELDN

Eledon Pharmaceuticals (ELDN)

Eledon Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ELDN
日付受信時刻ニュースソース見出しコード企業名
2024/06/1506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/06/1506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/06/1506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/06/1506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/06/0705 : 01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELDNEledon Pharmaceuticals Inc
2024/06/0613 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/06/0405 : 01GlobeNewswire Inc.Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/3105 : 25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/3105 : 05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/2505 : 02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/1520 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/1405 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/0920 : 30GlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/0920 : 00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/0720 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/0720 : 05GlobeNewswire Inc.Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/05/0720 : 00GlobeNewswire Inc.Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/03/2905 : 01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/03/2605 : 56GlobeNewswire Inc.Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/03/2123 : 31GlobeNewswire Inc.Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/02/1505 : 35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELDNEledon Pharmaceuticals Inc
2024/02/1505 : 01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
2024/02/1409 : 01GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
2024/01/0506 : 40GlobeNewswire Inc.Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookNASDAQ:ELDNEledon Pharmaceuticals Inc
2023/12/0508 : 00GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
2023/11/3006 : 05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
2023/11/1007 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
2023/11/1006 : 01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
2023/11/0906 : 05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
2023/11/0305 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELDN

最近閲覧した銘柄

NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
NYSE
VZ
Verizon Communications
NASDAQ
AMZN
Amazon.com
AMEX
SPY
SPDR S&P 500
NYSE
XOM
Exxon Mobil
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
NASDAQ
GOOGL
Alphabet
AMEX
XLE
Energy Select Sector SPDR
PM
XAUUSD
Gold vs US Dollar
NASDAQ
MSFT
Microsoft
NASDAQ
TSLA
Tesla
USOTC
BNPQY
BNP Paribas (QX)
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有